Obesity treatment shifts toward oral medications and dietary integration

The landscape of obesity and type 2 diabetes treatment is evolving with the development of oral medications designed to complement or replace traditional injectable GLP-1 agonists. New oral options include Eli Lilly’s orforglipron, which has been approved in the United States following clinical trials showing an average weight loss of 11.2% in adults, and AstraZeneca’s elecoglipron, which is advancing through clinical development.

Medical experts emphasize that while these medications are powerful tools for metabolic control, they are not standalone solutions. Clinical concerns include the risk of significant muscle mass loss due to rapid weight reduction and the potential for a rebound effect if treatment is discontinued without lifestyle changes. Nutritionists highlight the necessity of dietary re-education and protein management to preserve muscle mass and ensure long-term health success.